Composition, form of production and packaging
The solution for infusions is transparent, almost colorless.
D, L-aspartic acid 15.16 g
potassium hydroxide (co-85%) 3.854 g
magnesium oxide 1.116 g
Auxiliary substances: xylitol - 16.7 g, water d / and - 976.2 g.
250 ml - glass bottles (10) - cardboard boxes.
500 ml - glass bottles (10) - cardboard boxes.
250 ml - polyethylene bottles (10) - cardboard boxes.
500 ml - polyethylene bottles (10) - cardboard boxes.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2008.
Means that affect metabolic processes. The drug that replenishes the deficiency of potassium and magnesium ions in the body.
Potassium is one of the most common cations in the human body. The combination of K + and Mg 2+ takes part in many processes in the body: excitability and conductivity of nerve and muscle fibers, cellular metabolism, cardiac activity, water-electrolyte balance, renal function.
The asparaginates transfer ions K + and Mg 2+ and promote their penetration into the intracellular space. Entering the cells, aspartate is included in the metabolic processes.
The drug improves the metabolism in the myocardium, increases the tolerability of cardiac glycosides. Has antiarrhythmic activity.
Data on the pharmacokinetics of the drug are not available.
To eliminate the deficiency of potassium and magnesium in the combination therapy with the following diseases:
- IHD, incl. acute myocardial infarction;
- heart failure (as part of combination therapy);
- violations of the heart rhythm, incl. arrhythmias caused by an overdose of cardiac glycosides (as part of combination therapy);
The drug is only for IV administration.
The dose is selected individually, depending on the indications. The average recommended daily dose is 1-2 IV infusion per 500 ml infusion solution. The rate of administration is 15-45 drops / min, depending on individual tolerability.
One week before the cardiosurgical intervention and within a week after the operation, 500 ml of the drug per day is administered to the heart.
With rapid on / in the introduction of symptoms of hyperkalemia and hypermagnesemia.
From the musculoskeletal system: muscle weakness.
From the side of the central nervous system: fatigue, paresis, coma, lack of reflexes.
From the digestive system: nausea, vomiting.
From the side of the cardiovascular system: a violation of the conductivity of the myocardium; in rare cases - a paradoxical reaction in the form of an increase in the number of extrasystoles.
When observing the recommended rate of IV injections, no side effects were observed.
acute and chronic renal failure;
- Insufficiency of the adrenal cortex;
- AV blockade of I-III degree;
- Oliuria, anuria;
- Acute metabolic acidosis;
- Myasthenia gravis;
- arterial hypotension;
- Addison's disease;
- Hypersensitivity to the drug (including sorbitol).
With special care and only after a thorough assessment of the benefit-risk ratio, the drug should be prescribed for severe violations of liver function, metabolic acidosis, the risk of edema, renal dysfunction (when it is not possible to monitor serum magnesium regularly), hypophosphatemia, urolithic diathesis with a violation of the exchange of calcium, magnesium and ammonium phosphate.
PREGNANCY AND LACTATION
With special care and only after a careful assessment of the relationship between benefit and risk, the drug should be given during pregnancy and lactation.
APPLICATION FOR FUNCTIONS OF THE LIVER
With special caution and only after a thorough assessment of the relationship between benefit and risk, the drug should be prescribed for violations of kidney function (if it is not possible to regularly monitor the magnesium level in the serum).
Contraindicated in acute and chronic renal failure
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
With special care and only after a thorough assessment of the ratio of benefit and risk, the drug should be prescribed for severe violations of liver function.
For IV infusion, you can use only clear solutions in intact vials. After opening the vial, the solution should be used immediately.
If, when mixed with other injectable or infusion solutions, turbidity or opalescence appears, such mixtures can not be used.
With rapid on / in the introduction or administration of the drug at doses that significantly exceed the therapeutic potential for the development of symptoms ofhyperkalemia (muscle hypotension, paresthesia of the limbs, AV conduction slowing, arrhythmias, cardiac arrest) and hypermagnia (hyperemia of the face, thirst, violation of the neuromuscular transmission, oppression of the respiratory center, arrhythmia, convulsions).
Treatment: immediate cancellation of the drug, the introduction of 10% calcium gluconate solution, symptomatic therapy for the correction of cardiovascular disorders. If necessary, hemodialysis is performed.
With the simultaneous use of potassium-sparing diuretics and / or ACE inhibitors, hyperkalaemia and hypermagnesemia may occur.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored in a dry place inaccessible to children at a temperature of 15 В° to 25 В° C. Do not freeze! Shelf life - 2 years.